Archives of Pediatric Infectious Diseases

Published by: Kowsar

The Importance of Pyrazinamide in Antimycobacterial Combination Therapy of BCG Disease: Do We Need a Treatment Guideline in The Future?

Ikhwanuliman Putera 1 , * and Ikrar Syahmar 1
Authors Information
1 Faculty of Medicine,University of Indonesia, Jakarta, Indonesia
Article information
  • Archives of Pediatric Infectious Diseases: October 01, 2015, 3 (4); e30478
  • Published Online: September 16, 2015
  • Article Type: Letter
  • Received: June 2, 2015
  • Accepted: June 4, 2015
  • DOI: 10.5812/pedinfect.30478

To Cite: Putera I, Syahmar I. The Importance of Pyrazinamide in Antimycobacterial Combination Therapy of BCG Disease: Do We Need a Treatment Guideline in The Future?, Arch Pediatr Infect Dis. 2015 ; 3(4):e30478. doi: 10.5812/pedinfect.30478.

Copyright © 2015, Pediartric Infections Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnote
References
  • 1. The Global Plan to Stop TB 2006-2015. 2015;
  • 2. Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci. 2005; 1062: 69-78[DOI][PubMed]
  • 3. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009; 53(1): 316-8[DOI][PubMed]
  • 4. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guerin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis. 2008; 12(6)-105[DOI][PubMed]
  • 5. Roxo-Junior P, Silva J, Andrea M, Oliveira L, Ramalho F, Bezerra T, et al. A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficiency. Ital J Pediatr. 2013; 39: 54[DOI][PubMed]
  • 6. Fahimzad SA, Ghasemi M, Shiva F, Ghadiri K, Navidinia M, Karimi A. Susceptibility Pattern of Bacille Calmette-Guerin Strains Against Pyrazinamide and Other Major Anti-Mycobacterial Drugs. Arch Pediatr. 2015; 3(1): 17814
  • 7. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006; 42(4): 548-58[DOI][PubMed]
  • 8. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ. 2009; 87(7): 505-11[PubMed]
  • 9. Archibald LK, Kazembe PN, Nwanyanwu O, Mwansambo C, Reller LB, Jarvis WR. Epidemiology of bloodstream infections in a bacille Calmette-Guerin-vaccinated pediatric population in Malawi. J Infect Dis. 2003; 188(2): 202-8[DOI][PubMed]
  • 10. Chan WM, Kwan YW, Leung CW. Management of Bacillus Calmette-Guérin Lymphadenitis. HK J Paediatr. 2011; 16(2): 85-94
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments